FDA Approval Alert: The Need-to-Know | Cosibelimab in Cutaneous Squamous Cell Carcinoma

In December 2024, the FDA approved a resubmitted biologics license application for cosibelimab (Unloxcyt) as a treatment option for patients with locally advanced or metastatic cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiotherapy.

Cosibelimab Shows Promising Efficacy and Safety in Cutaneous CSCC
Cosibelimab Shows Promising Efficacy and Safety in Cutaneous CSCC
Video
Dec 16, 2024 9:00 PM
Objective response data from the CK-301-101 trial supports cosibelimab’s approval by the FDA, according to Jason J. Luke, MD, FACP.
Cosibelimab has been approved by the FDA as a treatment for patients with cutaneous squamous cell carcinoma.
FDA Approves Cosibelimab in Cutaneous Squamous Cell Carcinoma
Article
Dec 13, 2024 11:27 PM
Cosibelimab has been approved by the FDA as a treatment for patients with cutaneous squamous cell carcinoma.